Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (2): 161-164.doi: 10.35541/cjd.20201028
• Perspective • Previous Articles Next Articles
Song Zhiqiang, Wang Huan
Received:2020-10-21
Revised:2020-12-01
Online:2021-02-15
Published:2021-01-29
Contact:
Song Zhiqiang
E-mail:zhiqiang.song@hotmail.com
Song Zhiqiang, Wang Huan. Advances in the treatment of atopic dermatitis: new medications, new methods and new models[J]. Chinese Journal of Dermatology, 2021, 54(2): 161-164.doi:10.35541/cjd.20201028
| [1] | 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000. |
| [2] | Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis[J]. J Am Acad Dermatol, 2014,70(2):338⁃351. doi: 10.1016/j.jaad.2013.10.010. |
| [3] | Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II[J]. J Eur Acad Dermatol Venereol, 2012,26(9):1176⁃1193. doi: 10.1111/j.1468⁃3083.2012.04636.x. |
| [4] | Ahn K, Kim BE, Kim J, et al. Recent advances in atopic dermatitis[J]. Curr Opin Immunol, 2020,66:14⁃21. doi: 10.1016/j.coi.2020.02.007. |
| [5] | Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS[J]. J Am Acad Dermatol, 2020,82(6):1328⁃1336. doi: 10.1016/j.jaad.2020.02.060. |
| [6] | Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open⁃label study of adults with moderate⁃to⁃severe atopic dermatitis[J]. Am J Clin Dermatol, 2020,21(4):567⁃577. doi: 10.1007/s40257⁃020⁃00527⁃x. |
| [7] | de Bruin⁃Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo⁃controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)[J]. Br J Dermatol, 2018,178(5):1083⁃1101. doi: 10.1111/bjd.16156. |
| [8] | Wang C, Kraus CN, Patel KG, et al. Real⁃world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients′ records[J]. Int J Dermatol, 2020,59(2):253⁃256. doi: 10.1111/ijd.14573. |
| [9] | Wollenberg A, Howell MD, Guttman⁃Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti⁃IL⁃13 mAb[J]. J Allergy Clin Immunol, 2019,143(1):135⁃141. doi: 10.1016/j.jaci. 2018.05.029. |
| [10] | Pavel AB, Song T, Kim HJ, et al. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2019,144(4):1011⁃1024. doi: 10.1016/j.jaci.2019.07.013. |
| [11] | Bissonnette R, Maari C, Forman S, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate⁃to⁃severe atopic dermatitis: results from a randomized double⁃blind placebo⁃controlled study[J]. Br J Dermatol, 2019,181(4):733⁃742. doi: 10.1111/bjd.17932. |
| [12] | Silverberg JI, Tallman AM, Ports WC, et al. Evaluating the efficacy of crisaborole using the atopic dermatitis severity index and percentage of affected body surface area[J]. Acta Derm Venereol, 2020,100(13):adv00170. doi: 10.2340/00015555⁃3489. |
| [13] | Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream[J]. J Allergy Clin Immunol, 2020,145(2):572⁃582. doi: 10.1016/j.jaci.2019.08.042. |
| [14] | Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis[J]. Sci Transl Med, 2017,9(378):eaah4680. doi: 10.1126/scitranslmed.aah4680. |
| [15] | Yoo J, Choi JY, Lee BY, et al. Therapeutic effects of saline groundwater solution baths on atopic dermatitis: a pilot study[J]. Evid Based Complement Alternat Med, 2020,2020:8303716. doi: 10.1155/2020/8303716. |
| [16] | Maarouf M, Shi VY. Bleach for atopic dermatitis[J]. Dermatitis, 2018,29(3):120⁃126. doi: 10.1097/DER.0000000000000358. |
| [17] | Fishbein AB, Lor J, Penedo FJ, et al. Patient⁃reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: cross sectional study of PROMIS pediatric sleep measures and actigraphy[J]. J Am Acad Dermatol, 2020,S0190⁃9622(20)31015⁃X. doi: 10.1016/j.jaad. 2020.05.138. |
| [18] | Gustafson CJ, O′Neill J, Hix E, et al. Feasibility of actigraphy wristband monitoring of atopic dermatitis in children[J]. Skin Res Technol, 2014,20(4):510⁃514. doi: 10.1111/srt.12147. |
| [19] | Dong B, Ren A, Shah SA, et al. Monitoring of atopic dermatitis using leaky coaxial cable[J]. Healthc Technol Lett, 2017,4(6):244⁃248. doi: 10.1049/htl.2017.0021. |
| [20] | Eto H, Tsuji G, Chiba T, et al. Non⁃invasive evaluation of atopic dermatitis based on redox status using in vivo dynamic nuclear polarization magnetic resonance imaging[J]. Free Radic Biol Med, 2017,103:209⁃215. doi: 10.1016/j.freeradbiomed.2016.12. 043. |
| [21] | Wenninger K, Kehrt R, von Rüden U, et al. Structured parent education in the management of childhood atopic dermatitis: the Berlin model[J]. Patient Educ Couns, 2000,40(3):253⁃261. doi: 10.1016/s0738⁃3991(99)00074⁃9. |
| [22] | van Os⁃Medendorp H, Deprez E, Maes N, et al. The role of the nurse in the care and management of patients with atopic dermatitis[J]. BMC Nurs, 2020,19(1):102. doi: 10.1186/s12912⁃020⁃00494⁃y. |
| [23] | 赖沙, 王华. 特应性皮炎治疗中的患者教育和管理[J]. 国际皮肤性病学杂志, 2013,39(4):255⁃257. doi: 10.3760/cma.j.issn. 1673⁃4173.2013.04.014. |
| [24] | 蒲晓英. 全程健康教育对银屑病患者生活质量的影响[J]. 中国医疗前沿, 2013,(10):110⁃111. doi: 10.3969/j.issn.1673⁃5552. 2013.10.0082. |
| [1] | Mycobacteriosis Research Group, China “Belt and Road” Dermatology Alliance, Division of Dermatology and STI Diagnosis, Chinese Association on Leprosy. Expert consensus on the clinical diagnosis and treatment of cutaneous tuberculosis in China (2024) [J]. Chinese Journal of Dermatology, 2024, 57(5): 426-434. |
| [2] | Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358. |
| [3] | Liu Yi, Qu Ying, Lei Wenzhi, Liu Xiaogang, Pan Weihua, Zhang Chao. Clinical efficacy of salt-packing therapy in the treatment of pyogenic granuloma [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230553-e20230553. |
| [4] | Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354. |
| [5] | Tian Jing, Deng Sisi, Song Zhiqiang . A comparison of clinical characteristics between atopic and non-atopic prurigo nodularis [J]. Chinese Journal of Dermatology, 2024, 57(4): 331-337. |
| [6] | Ge Xinhong, Ma Yingdong, Jiao Yaning, Liu Lingling, Zhou Mei, Zi Wei, Li Bowen. Analysis of efficacy and safety of 532-nm picosecond laser in the treatment of early-stage facial seborrheic keratosis [J]. Chinese Journal of Dermatology, 2024, 57(4): 359-362. |
| [7] | Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378. |
| [8] | Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429. |
| [9] | Dai Yeqin, Song Xiuzu. Application of hair follicle transplantation and follicular cell suspension transplantation in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230274-e0230274. |
| [10] | Li Yuanjun, Han Yuyang, Zhang Huanzhen, Wang Hui, Shen Nan, Zhang Xinglian. Dupilumab in the treatment of 12 children with chronic spontaneous urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(3): 254-257. |
| [11] | Hospital for Skin Diseases, Chinese Academy of Medical Sciences, National Center for STD Control, Chinese Center for Disease Control and Prevention, Venereology Group, Chinese Society of Dermatology, Chinese Association Rehabilitation of Dermatology . Chinese expert consensus on the diagnosis and treatment of Mycoplasma genitalium infection (2024) [J]. Chinese Journal of Dermatology, 2024, 57(3): 201-208. |
| [12] | Wang Qianqiu, Zheng Xiaoli, Du Fangzhi, Zhang Xu. Stop syphilis transmission: new situation and new strategies [J]. Chinese Journal of Dermatology, 2024, 57(3): 209-212. |
| [13] | Chinese Society of Dermatology, National Center for STD Control, Chinese Center for Disease Control and Prevention, China Dermatologist Association, Chinese Association Rehabilitation of Dermatology. Guideline for the diagnosis and treatment of Chlamydia trachomatis urogenital infection in China (2024) [J]. Chinese Journal of Dermatology, 2024, 57(3): 193-200. |
| [14] | Liu Jia, Gu Yinghua, He Xiaoning, . Treatment and disease burden of hereditary angioedema [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220205-e20220205. |
| [15] | Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578. |
|